MRNA-5671 explained

Drug Name:mRNA-5671
Type:vaccine
Target:Cancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene
Vaccine Type:mRNA
Routes Of Administration:Intramuscular

mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna.[1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene.[2] It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.
In 2021 Merck dropped the trial,[3] [4] and clinicaltrials.gov study NCT03948763 ended 2022-08-25.[5] As of May 2024, no further progress on this vaccine has been announced.

Notes and References

  1. Web site: mRNA 5671 . AdisInsight . Springer Nature Switzerland AG.
  2. Web site: mRNA-derived KRAS-targeted vaccine V941 . National Cancer Institute Dictionaries . National Institutes of Health, U.S. Department of Health and Human Services .
  3. https://www.fiercebiotech.com/biotech/merck-cuts-ties-modernas-early-phase-kras-vaccine-leaving-mrna-specialist-mull-next-steps
  4. Web site: Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates .
  5. Web site: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma . 5 September 2022 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MRNA-5671".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.